Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow morphologic changes after combination chemotherapy including VP-16.

D J Adelstein, J D Hines

    Cancer
    |August 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

    Leukemia·2017
    Same author

    It is not just IMRT: Human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy.

    Oral oncology·2015
    Same author

    Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials.

    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2014
    Same author

    Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.

    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2012
    Same author

    Is there a role for folate determinations in current clinical practice in the USA?

    Clinical and laboratory haematology·2004
    Same author

    P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.

    The Laryngoscope·2002
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Chemotherapy with VP-16 in small cell lung cancer patients caused unique bone marrow changes, including disrupted cell division and death, despite no clear link to toxicity. Further research is needed due to the small sample size.

    Area of Science:

    • Oncology
    • Hematology
    • Pharmacology

    Background:

    • Small cell lung cancer (SCLC) is often treated with combination chemotherapy.
    • VP-16 (etoposide) is a key chemotherapeutic agent used in SCLC treatment.
    • Understanding the specific effects of chemotherapy on bone marrow is crucial for managing toxicity.

    Purpose of the Study:

    • To investigate the bone marrow morphologic changes in SCLC patients treated with VP-16.
    • To explore potential correlations between these changes and hematologic toxicity.
    • To assess the impact of VP-16 on bone marrow cellularity and cell division.

    Main Methods:

    • Examination of bone marrow aspirates and biopsy specimens from seven SCLC patients.
    • Patients had received recent combination chemotherapy including VP-16.

    Related Experiment Videos

  • Morphologic analysis focused on cellularity, M:E ratio, cell division, and cell death.

    • Main Results:

    • No direct correlation was found between bone marrow biopsy cellularity and hematologic toxicity.
    • Observed unusual morphologic changes: increased M:E ratio, disrupted cell division, and cell death.
    • Minimal evidence of mitotic arrest or megaloblastosis was noted.

    Conclusions:

    • Observed bone marrow changes are consistent with VP-16's known mechanism of action.
    • The study suggests VP-16 significantly impacts bone marrow cell kinetics.
    • Limited conclusions are drawn due to small sample size and confounding chemotherapy agents.